BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, October 2, 2023
Home » Blogs » BioWorld Perspectives » The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

The Biotech Toddler Argument: “Chilling Effect on Innovation” Overplayed?

Nov. 18, 2011
By Trista Morrison
No Comments

In last week’s issue of BioWorld Insight, our esteemed Washington editor Mari Serebrov wrote an article titled, “Shorter Exclusivity Could Carry a Hefty Price Tag.” In it, she quoted sources who are very concerned that reducing the current 12-year exclusivity for innovator biologics to seven years, as the president and a number of lawmakers have proposed, would be bad news for patients, payers and drug makers.

In the article, Mary Webster, a patent attorney with Nixon Peabody, said: "If you can't corner your market and recoup your costs, are you going to do it?"

And suddenly I had a flashback to negotiating with my three-year-old:

Me: “No you can’t have a cookie for dinner.”

Toddler: [crossing arms and stamping foot] “Fine, then I’m not going to eat anything for dinner.”

This scene has replayed itself in my head several times recently as I’ve written about biotech news – i.e. when gene patents are questioned, or reimbursement policies are debated, or drug importation gains traction, or the FDA shifts its stance on something. Each time, the industry’s response is to threaten that these moves will result in a “chilling effect on innovation” (translation: mess with us and we’ll stop making drugs).

Don’t get me wrong, I think the biotechnology industry deserves every advantage. But if biologics end up with seven years of exclusivity, do we really think companies will stop making them? Really? When biologics account for many of the top-selling drugs, each raking in multi-billions of dollars annually?

I worry that biopharma firms aren’t winning any points in the court of public opinion by stamping their feet and threatening to stop innovating every time something they don’t like gets put on the table. This approach certainly hasn’t worked for my toddler: When he threatens that he’s not going to eat dinner, I say, “fine, don’t eat” – and within minutes he’s seated at the table, munching away on his veggies.

You know what did work, though? When he said, “What if I eat a good dinner? Then can I have a cookie?” Negotiation is a fact of life – everybody has to give and take. My three-year old figured it out. Maybe it’s time for the industry to follow suit.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 29, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 29, 2023.
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Man measuring waist

    Structure challenges Lilly, Pfizer, with oral GLP-1 data; raises $300M

    BioWorld
    Structure Therapeutics Inc.’s stock climbed 34.6% following a readout of what analysts call “competitive” and “exceptional” phase Ib data at 28 days of oral...
  • Art concept for gene therapy research

    Machine learning tool Alphamissense analyzes human mutations to predict diseases

    BioWorld
    Proteome analysis with artificial intelligence has made it possible to create a catalog of all possible missense mutations in the human genome to predict...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing